A single intranasal administration of virus-like particle vaccine induces an efficient protection for mice against human respiratory syncytial virus

Antiviral Research
Yue-Ying JiaoJin-Sheng He

Abstract

Human respiratory syncytial virus (RSV) is an important pediatric pathogen causing acute viral respiratory disease in infants and young children. However, no licensed vaccines are currently available. Virus-like particles (VLPs) may bring new hope to producing RSV VLP vaccine with high immunogenicity and safety. Here, we constructed the recombinants of matrix protein (M) and fusion glycoprotein (F) of RSV, respectively into a replication-deficient first-generation adenoviral vector (FGAd), which were used to co-infect Vero cells to assemble RSV VLPs successfully. The resulting VLPs showed similar immunoreactivity and function to RSV virion in vitro. Moreover, Th1 polarized response, and effective mucosal virus-neutralizing antibody and CD8+T-cell responses were induced by a single intranasal (i.n.) administration of RSV VLPs rather than intramuscular (i.m.) inoculation, although the comparable RSV F-specific serum IgG and long-lasting RSV-specific neutralizing antibody were detected in the mice immunized by both routes. Upon RSV challenge, VLP-immunized mice showed increased viral clearance but decreased signs of enhanced lung pathology and fewer eosinophils compared to mice immunized with formalin-inactivated RSV (FI-RSV). In ...Continue Reading

Citations

Aug 12, 2017·International Journal of Molecular Sciences·Nicolás M S GálvezAlexis M Kalergis
Sep 4, 2018·Expert Review of Vaccines·Braeden DonaldsonVernon K Ward
Oct 20, 2018·Minerva pediatrica·Anna C VittucciAlberto Villani
Jul 17, 2018·Current Clinical Microbiology Reports·Carolyn M Clark, Antonieta Guerrero-Plata

❮ Previous
Next ❯